数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Brenton L. Saunders Chairman, President and Chief Executive Officer 49 413.90万美元 未持股 2019-02-15
Adriane M. Brown Director 65 未披露 未持股 2019-02-15
Joseph H. Boccuzi -- Director -- 未披露 未持股 2019-02-15
Carol Anthony Davidson -- Director -- 未披露 未持股 2019-02-15
Michael E. Greenberg -- Director -- 未披露 未持股 2019-02-15
Thomas C. Freyman -- Director -- 未披露 未持股 2019-02-15
Patricia Haran -- Director -- 未披露 未持股 2019-02-15
Donnan Hurst -- Director -- 未披露 未持股 2019-02-15
Catherine M. Klema Director 65 49.98万美元 未持股 2019-02-15
Christopher J. Coughlin Director 71 44.98万美元 未持股 2019-02-15
Nesli Basgoz Director 66 47.38万美元 未持股 2019-02-15
Christopher W. Bodine Director 68 71.05万美元 未持股 2019-02-15
Peter J. McDonnell Director 65 44.98万美元 未持股 2019-02-15

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Brenton L. Saunders Chairman, President and Chief Executive Officer 49 413.90万美元 未持股 2019-02-15
C. David Nicholson Executive Vice President and Chief R&D Officer 64 未披露 未持股 2019-02-15
James C. D'Arecca Chief Accounting Officer 48 未披露 未持股 2019-02-15
William Meury Executive Vice President and Chief Commercial Officer 51 168.61万美元 未持股 2019-02-15
A. Robert D. Bailey Executive Vice President and Chief Legal Officer and Corporate Secretary 55 未披露 未持股 2019-02-15
Matthew M. Walsh Executive Vice President and Chief Financial Officer 52 未披露 未持股 2019-02-15
Karen L. Ling Executive Vice President and Chief Human Resources Officer 55 未披露 未持股 2019-02-15
Wayne R. Swanton Executive Vice President, Global Operations 51 未披露 未持股 2019-02-15
James C. D'Arecca Chief Accounting Officer 48 未披露 未持股 2019-02-15
Karen Ling Executive Vice President and Chief Human Resources Officer 55 未披露 未持股 2019-02-15

董事简历

中英对照 |  中文 |  英文
Brenton L. Saunders

Brenton L. Saunders,自2010三月起担任博士伦首席执行官和董事。此前,2003-2010,他担任先灵葆雅的高级执行官,最近的职务是全球消费者保健总裁。先灵葆雅与默克公司的合并,及160亿美元收购欧加农生物公司这两项并购业务,他都是负责人。在加入先灵葆雅之前,2000-2003,他担任普华永道的董事,及合规经营咨询部的负责人。在这之前,1998-1999,他是Coventry Health Carer的首席风险官;1995,他成为Health Care Compliance Association的合伙人。他在托马斯杰弗逊大学卫生系统开始职业生涯,担任首席合规官。除了担任博士伦董事,他还在ElectroCore LLC,the Overlook Hospital Foundation出任董事。他还是美国心脏协会纽约分会的前主席。他还是联邦储备银行纽约州北部地区咨询委员会,美国药物研究和制造商协会,和商业协会的成员。他担任着匹兹堡大学理事会成员。他获得了匹兹堡大学的学士学位,天普大学商学院工商管理硕士学位,天普大学法学院法学博士学位。


Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business.
Brenton L. Saunders,自2010三月起担任博士伦首席执行官和董事。此前,2003-2010,他担任先灵葆雅的高级执行官,最近的职务是全球消费者保健总裁。先灵葆雅与默克公司的合并,及160亿美元收购欧加农生物公司这两项并购业务,他都是负责人。在加入先灵葆雅之前,2000-2003,他担任普华永道的董事,及合规经营咨询部的负责人。在这之前,1998-1999,他是Coventry Health Carer的首席风险官;1995,他成为Health Care Compliance Association的合伙人。他在托马斯杰弗逊大学卫生系统开始职业生涯,担任首席合规官。除了担任博士伦董事,他还在ElectroCore LLC,the Overlook Hospital Foundation出任董事。他还是美国心脏协会纽约分会的前主席。他还是联邦储备银行纽约州北部地区咨询委员会,美国药物研究和制造商协会,和商业协会的成员。他担任着匹兹堡大学理事会成员。他获得了匹兹堡大学的学士学位,天普大学商学院工商管理硕士学位,天普大学法学院法学博士学位。
Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business.
Adriane M. Brown

Adriane M. Brown,她于2017年加入eBay Inc.的董事会。她目前是Intellectual Ventures LLC(Intellectual Ventures)的总裁兼首席运营官。加入Intellectual Ventures之前,她曾担任Honeywell International, Inc. (Honeywell) 的多种领导职务(1999年至2010年),最近担任高级副总裁,负责能源战略,此前曾担任Honeywell公司的交通运输系统全球运营集团的总裁兼首席执行官。加入Honeywell公司之前,她曾任职Corning, Inc.19年,最终担任副总裁兼环境产品事业部总经理,在那里开始了她的轮班主管的职业生涯。她获得Old Dominion University的环境健康方面的科学学士学位,以及Massachusetts Institute of Technology的管理学硕士学位(斯隆研究员)。她也获得Old Dominion University的人文主义文学的博士学位。


Adriane M. Brown,joined Flying Fish Ventures, as a Venture Partner in November 2018 and in early 2021 became a Managing Partner of the venture capital firm, which specialized in Artificial Intelligence and Machine Learning startups. Prior to that, Ms. Brown served as President and Chief Operating Officer for Intellectual Ventures ("IV"), an invention and investment company that commercializes inventions, from January 2010 through July 2017, and served as a Senior Advisor until December 2018. Before joining IV, Ms. Brown served as President and Chief Executive Officer of Honeywell Transportation Systems. Over the course of 10 years at Honeywell, she held leadership positions serving the aerospace and automotive markets globally. Prior to Honeywell, Ms. Brown spent 19 years at Corning, Inc., ultimately serving as Vice President and General Manager, Environmental Products Division, having started her career there as a shift supervisor.Ms. Brown serves on the boards of directors of American Airlines Group, Inc., Axon Enterprise, Inc., KKR & Co. Inc., and the non-profit International Women's Forum. Ms. Brown previously served on the boards of directors of Allergan Plc, and Raytheon Company until 2020 and Harman International Industries from 2013 to 2017.Ms. Brown holds a Doctorate of Humane Letters and a bachelor's degree in environmental health from Old Dominion University and is a recipient of its Distinguished Alumni Award. She also holds a master's degree in management from the Massachusetts Institute of Technology where she was a Sloan Fellow.
Adriane M. Brown,她于2017年加入eBay Inc.的董事会。她目前是Intellectual Ventures LLC(Intellectual Ventures)的总裁兼首席运营官。加入Intellectual Ventures之前,她曾担任Honeywell International, Inc. (Honeywell) 的多种领导职务(1999年至2010年),最近担任高级副总裁,负责能源战略,此前曾担任Honeywell公司的交通运输系统全球运营集团的总裁兼首席执行官。加入Honeywell公司之前,她曾任职Corning, Inc.19年,最终担任副总裁兼环境产品事业部总经理,在那里开始了她的轮班主管的职业生涯。她获得Old Dominion University的环境健康方面的科学学士学位,以及Massachusetts Institute of Technology的管理学硕士学位(斯隆研究员)。她也获得Old Dominion University的人文主义文学的博士学位。
Adriane M. Brown,joined Flying Fish Ventures, as a Venture Partner in November 2018 and in early 2021 became a Managing Partner of the venture capital firm, which specialized in Artificial Intelligence and Machine Learning startups. Prior to that, Ms. Brown served as President and Chief Operating Officer for Intellectual Ventures ("IV"), an invention and investment company that commercializes inventions, from January 2010 through July 2017, and served as a Senior Advisor until December 2018. Before joining IV, Ms. Brown served as President and Chief Executive Officer of Honeywell Transportation Systems. Over the course of 10 years at Honeywell, she held leadership positions serving the aerospace and automotive markets globally. Prior to Honeywell, Ms. Brown spent 19 years at Corning, Inc., ultimately serving as Vice President and General Manager, Environmental Products Division, having started her career there as a shift supervisor.Ms. Brown serves on the boards of directors of American Airlines Group, Inc., Axon Enterprise, Inc., KKR & Co. Inc., and the non-profit International Women's Forum. Ms. Brown previously served on the boards of directors of Allergan Plc, and Raytheon Company until 2020 and Harman International Industries from 2013 to 2017.Ms. Brown holds a Doctorate of Humane Letters and a bachelor's degree in environmental health from Old Dominion University and is a recipient of its Distinguished Alumni Award. She also holds a master's degree in management from the Massachusetts Institute of Technology where she was a Sloan Fellow.
Joseph H. Boccuzi
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Carol Anthony Davidson
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Michael E. Greenberg
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Thomas C. Freyman
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Patricia Haran
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Donnan Hurst
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Catherine M. Klema

Catherine M. Klema,2004年起,担任Actavis, Inc.的董事,于2013年10月加入本公司董事会。她现为Nettleton Advisors LLC的总裁,这是她在2001年成立的咨询公司。成立该公司之前,1997-2001,她是SG Cowen Securities卫生保健投资银行业务的董事总经理;1994-1997,担任Furman Selz LLC的卫生保健投资银行业务董事总经理;1987-1994,任职于Lehman Brothers;2000-2011,担任全球性研究承包机构Pharmaceutical Product Development, Inc.的董事。2012年3月,她被任命为Montefiore Medical Center的董事。


Catherine M. Klema joined the Board of Directors in 2004. She is currently President of Nettleton Advisors LLC, a consulting firm established by Ms. Klema in 2001. Prior to establishing her firm, Ms. Klema served as Managing Director, Healthcare Investment Banking, at SG Cowen Securities from 1997 to 2001. Ms. Klema also served as Managing Director, Healthcare Investment Banking, at Furman Selz LLC from 1994 until 1997 and was employed by Lehman Brothers from 1987 until 1994. Ms. Klema served as a director of Pharmaceutical Product Development, Inc., a global contract research organization, from 2000 to 2011.
Catherine M. Klema,2004年起,担任Actavis, Inc.的董事,于2013年10月加入本公司董事会。她现为Nettleton Advisors LLC的总裁,这是她在2001年成立的咨询公司。成立该公司之前,1997-2001,她是SG Cowen Securities卫生保健投资银行业务的董事总经理;1994-1997,担任Furman Selz LLC的卫生保健投资银行业务董事总经理;1987-1994,任职于Lehman Brothers;2000-2011,担任全球性研究承包机构Pharmaceutical Product Development, Inc.的董事。2012年3月,她被任命为Montefiore Medical Center的董事。
Catherine M. Klema joined the Board of Directors in 2004. She is currently President of Nettleton Advisors LLC, a consulting firm established by Ms. Klema in 2001. Prior to establishing her firm, Ms. Klema served as Managing Director, Healthcare Investment Banking, at SG Cowen Securities from 1997 to 2001. Ms. Klema also served as Managing Director, Healthcare Investment Banking, at Furman Selz LLC from 1994 until 1997 and was employed by Lehman Brothers from 1987 until 1994. Ms. Klema served as a director of Pharmaceutical Product Development, Inc., a global contract research organization, from 2000 to 2011.
Christopher J. Coughlin

Christopher J. Coughlin,自2004年12月担任邓白氏董事会的主任,事务委员会的主席和薪酬福利委员会的成员。2010年8月至2013年10月他还担任董事会的主席。从2005年3月至2010年12月他担任一家消防和安全解决方案的全球领先者,泰科国际有限公司的执行副总裁和首席财务官,从2010年12月到2012年10月担任公司顾问。此前,从2003年6月到2004年12月他担任Interpublic集团股份有限公司的执行副总裁和首席运营官,从2003年8月至2004年6月作为首席财务官,从2003年7月到2004年7月担任总裁。在这之前,从1998年到2003年他担任法玛西亚公司的执行副总裁和首席财务官,在他担任执行副总裁之前,担任纳贝斯克国际一个部门的总裁。他目前担任麦肯锡公司的一位高级顾问,也是以下公共公司董事:Covidien有限责任公司, Forest实验室股份有限公司和Dipexium 制药股份有限公司,他在过去五年中没有担任任何其他公共公司的董事。他曾担任Perrigo公司,Monsanto公司和Interpublic公司集团股份有限公司的董事。


Christopher J. Coughlin,Senior Advisor to the CEO and Board of Directors of Tyco International from 2010 to his retirement in 2012.Executive Vice President and CFO of Tyco from 2005 to 2010, during which he was instrumental in turning the company around after a management and financial scandal and ultimately separated it into six separate public companies.Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004 and as Chief Financial Officer from August 2003 to June 2004.Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003.Named a 2022 Director of the Year by the New Jersey Chapter of the National Association of Corporate Directors (NACD) for his leadership in public corporate governance.Named the NACD Corporate Director of the Year in 2015.Received a Bachelor of Science from Boston College.
Christopher J. Coughlin,自2004年12月担任邓白氏董事会的主任,事务委员会的主席和薪酬福利委员会的成员。2010年8月至2013年10月他还担任董事会的主席。从2005年3月至2010年12月他担任一家消防和安全解决方案的全球领先者,泰科国际有限公司的执行副总裁和首席财务官,从2010年12月到2012年10月担任公司顾问。此前,从2003年6月到2004年12月他担任Interpublic集团股份有限公司的执行副总裁和首席运营官,从2003年8月至2004年6月作为首席财务官,从2003年7月到2004年7月担任总裁。在这之前,从1998年到2003年他担任法玛西亚公司的执行副总裁和首席财务官,在他担任执行副总裁之前,担任纳贝斯克国际一个部门的总裁。他目前担任麦肯锡公司的一位高级顾问,也是以下公共公司董事:Covidien有限责任公司, Forest实验室股份有限公司和Dipexium 制药股份有限公司,他在过去五年中没有担任任何其他公共公司的董事。他曾担任Perrigo公司,Monsanto公司和Interpublic公司集团股份有限公司的董事。
Christopher J. Coughlin,Senior Advisor to the CEO and Board of Directors of Tyco International from 2010 to his retirement in 2012.Executive Vice President and CFO of Tyco from 2005 to 2010, during which he was instrumental in turning the company around after a management and financial scandal and ultimately separated it into six separate public companies.Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004 and as Chief Financial Officer from August 2003 to June 2004.Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003.Named a 2022 Director of the Year by the New Jersey Chapter of the National Association of Corporate Directors (NACD) for his leadership in public corporate governance.Named the NACD Corporate Director of the Year in 2015.Received a Bachelor of Science from Boston College.
Nesli Basgoz

Nesli Basgoz, M.D.,现任马萨诸塞州总医院临床事务副主任,感染性疾病科副主任,并在该医院理事会任职。此外,她是哈佛医学院的药学副教授。此前,她曾在马萨诸塞州总医院传染病部担任了6年的临床主任。她获得了医学博士学位,在西北大学医学院内科完成她的专业。她还拿到了三藩市加利福尼亚大学传染病学科的奖学金。她是经认证的传染病和内科专业医生。


Nesli Basgoz joined the Board of Directors in July 2014 following the Company’s acquisition of Forest, having served as a member of the Board of Directors of Forest beginning 2006. Dr. Basgoz is currently the Associate Chief and Clinical Director, Division of Infectious Diseases at Massachusetts General Hospital MGH. In addition, Dr. Basgoz is an Associate Professor of Medicine at Harvard Medical School. Dr. Basgoz earned her MD degree and completed her residency in internal medicine at Northwestern University Medical School. She also completed a fellowship in the Infectious Diseases Division at the University of California at San Francisco. She is board certified in both infectious diseases and internal medicine.
Nesli Basgoz, M.D.,现任马萨诸塞州总医院临床事务副主任,感染性疾病科副主任,并在该医院理事会任职。此外,她是哈佛医学院的药学副教授。此前,她曾在马萨诸塞州总医院传染病部担任了6年的临床主任。她获得了医学博士学位,在西北大学医学院内科完成她的专业。她还拿到了三藩市加利福尼亚大学传染病学科的奖学金。她是经认证的传染病和内科专业医生。
Nesli Basgoz joined the Board of Directors in July 2014 following the Company’s acquisition of Forest, having served as a member of the Board of Directors of Forest beginning 2006. Dr. Basgoz is currently the Associate Chief and Clinical Director, Division of Infectious Diseases at Massachusetts General Hospital MGH. In addition, Dr. Basgoz is an Associate Professor of Medicine at Harvard Medical School. Dr. Basgoz earned her MD degree and completed her residency in internal medicine at Northwestern University Medical School. She also completed a fellowship in the Infectious Diseases Division at the University of California at San Francisco. She is board certified in both infectious diseases and internal medicine.
Christopher W. Bodine

Christopher W. Bodine,2009年起担任Actavis, Inc.董事会成员,2013年10月起进入本公司董事会。他在CVS工作了24年之后于2009年1月退休。退休之前,他是CVS Caremark Corporation医疗保健服务董事长,负责战略、业务发展、贸易关系、销售和帐户管理、制药销售、市场营销、信息技术和Minute Clinic。2007年3月CVS Corporation和Caremark Rx, Inc合并之前,他在CVS Corporation担任销售和市场营销执行副总裁。他现在活跃于制药工业,在很多公司的董事会和委员会担任职位,包括the Healthcare Leadership Council、RI Quality Institute、National Retail Federation、National Association of Chain Drug Stores NACDS、the NACDS Pharmacy Affairs 和Leadership Committees。他还曾是Nash Finch董事长。


Christopher W. Bodine,has served on Onewater Marine Inc. Board of Directors since the closing of Onewater Marine Inc. initial public offering (the "IPO"). Mr. Bodine retired as President, Health Care Services at CVS Health Corp (formerly CVS Caremark Corporation) (NYSE: CVS) ("CVS") after 24 years with CVS in 2009. During his tenure as President, Mr. Bodine was responsible for Strategy, Business Development, Trade Relations, Sales and Account Management, Pharmacy Merchandising, Marketing, Information Technology, and Minute Clinic. Mr. Bodine is currently Chairman and Director of Continuum RX Services, Inc. Mr. Bodine is also a Venture Partner at NewSpring Capital and a Director of Russell Medical Center Foundation. Prior to these positions, he was a director at Allergan Plc (NYSE: AGN), Fred's, Inc. (NASDAQ: FRED) and Nash-Finch Company. Mr. Bodine formerly served as a Trustee for Bryant University and is active with the Juvenile Diabetes Research Foundation and the American Heart Association. Mr. Bodine attended Troy State University and received an Honorary Doctorate Degree in Business Administration from Johnson & Wales University.
Christopher W. Bodine,2009年起担任Actavis, Inc.董事会成员,2013年10月起进入本公司董事会。他在CVS工作了24年之后于2009年1月退休。退休之前,他是CVS Caremark Corporation医疗保健服务董事长,负责战略、业务发展、贸易关系、销售和帐户管理、制药销售、市场营销、信息技术和Minute Clinic。2007年3月CVS Corporation和Caremark Rx, Inc合并之前,他在CVS Corporation担任销售和市场营销执行副总裁。他现在活跃于制药工业,在很多公司的董事会和委员会担任职位,包括the Healthcare Leadership Council、RI Quality Institute、National Retail Federation、National Association of Chain Drug Stores NACDS、the NACDS Pharmacy Affairs 和Leadership Committees。他还曾是Nash Finch董事长。
Christopher W. Bodine,has served on Onewater Marine Inc. Board of Directors since the closing of Onewater Marine Inc. initial public offering (the "IPO"). Mr. Bodine retired as President, Health Care Services at CVS Health Corp (formerly CVS Caremark Corporation) (NYSE: CVS) ("CVS") after 24 years with CVS in 2009. During his tenure as President, Mr. Bodine was responsible for Strategy, Business Development, Trade Relations, Sales and Account Management, Pharmacy Merchandising, Marketing, Information Technology, and Minute Clinic. Mr. Bodine is currently Chairman and Director of Continuum RX Services, Inc. Mr. Bodine is also a Venture Partner at NewSpring Capital and a Director of Russell Medical Center Foundation. Prior to these positions, he was a director at Allergan Plc (NYSE: AGN), Fred's, Inc. (NASDAQ: FRED) and Nash-Finch Company. Mr. Bodine formerly served as a Trustee for Bryant University and is active with the Juvenile Diabetes Research Foundation and the American Heart Association. Mr. Bodine attended Troy State University and received an Honorary Doctorate Degree in Business Administration from Johnson & Wales University.
Peter J. McDonnell

Peter J. McDonnell, 自2003年担任美国约翰霍普金斯大学医学院的Wilmer眼科研究所所长及威廉荷兰威尔默教授。他领导的这家Wilmer眼科研究所,是美国最大的学术眼科。自2004年以来,他还担任眼科时报的首席医疗编辑,并且是众多眼科杂志的编辑委员会成员。1996年,他曾担任美国国务院健康与人类服务的顾问。1987年至1988年,还在威尔默研究所担任服务助理院长。


Peter J. McDonnell joined the Board of Directors in March 2015 following the Company’s acquisition of Allergan, Inc., having served as a member of the Allergan, Inc. Board of Directors from 2013. Dr. McDonnell has been the Director and William Holland Wilmer Professor of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine since 2003. Dr. McDonnell has also served as the Chief Medical Editor of Ophthalmology Times since 2004 and has served on the editorial boards of numerous ophthalmology journals. Dr. McDonnell also served as the Assistant Chief of Service at the Wilmer Institute from 1987 to 1988. Dr. McDonnell also serves as the President and a director of the National Alliance for Eye and Vision Research and the Alliance for Eye and Vision Research. He served as a consultant to the United States Department of Health and Human Services in 1996. Dr. McDonnell served as a full-time faculty at the University of Southern California from 1988 until 1999 where he advanced to the rank of professor in 1994.
Peter J. McDonnell, 自2003年担任美国约翰霍普金斯大学医学院的Wilmer眼科研究所所长及威廉荷兰威尔默教授。他领导的这家Wilmer眼科研究所,是美国最大的学术眼科。自2004年以来,他还担任眼科时报的首席医疗编辑,并且是众多眼科杂志的编辑委员会成员。1996年,他曾担任美国国务院健康与人类服务的顾问。1987年至1988年,还在威尔默研究所担任服务助理院长。
Peter J. McDonnell joined the Board of Directors in March 2015 following the Company’s acquisition of Allergan, Inc., having served as a member of the Allergan, Inc. Board of Directors from 2013. Dr. McDonnell has been the Director and William Holland Wilmer Professor of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine since 2003. Dr. McDonnell has also served as the Chief Medical Editor of Ophthalmology Times since 2004 and has served on the editorial boards of numerous ophthalmology journals. Dr. McDonnell also served as the Assistant Chief of Service at the Wilmer Institute from 1987 to 1988. Dr. McDonnell also serves as the President and a director of the National Alliance for Eye and Vision Research and the Alliance for Eye and Vision Research. He served as a consultant to the United States Department of Health and Human Services in 1996. Dr. McDonnell served as a full-time faculty at the University of Southern California from 1988 until 1999 where he advanced to the rank of professor in 1994.

高管简历

中英对照 |  中文 |  英文
Brenton L. Saunders

Brenton L. Saunders,自2010三月起担任博士伦首席执行官和董事。此前,2003-2010,他担任先灵葆雅的高级执行官,最近的职务是全球消费者保健总裁。先灵葆雅与默克公司的合并,及160亿美元收购欧加农生物公司这两项并购业务,他都是负责人。在加入先灵葆雅之前,2000-2003,他担任普华永道的董事,及合规经营咨询部的负责人。在这之前,1998-1999,他是Coventry Health Carer的首席风险官;1995,他成为Health Care Compliance Association的合伙人。他在托马斯杰弗逊大学卫生系统开始职业生涯,担任首席合规官。除了担任博士伦董事,他还在ElectroCore LLC,the Overlook Hospital Foundation出任董事。他还是美国心脏协会纽约分会的前主席。他还是联邦储备银行纽约州北部地区咨询委员会,美国药物研究和制造商协会,和商业协会的成员。他担任着匹兹堡大学理事会成员。他获得了匹兹堡大学的学士学位,天普大学商学院工商管理硕士学位,天普大学法学院法学博士学位。


Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business.
Brenton L. Saunders,自2010三月起担任博士伦首席执行官和董事。此前,2003-2010,他担任先灵葆雅的高级执行官,最近的职务是全球消费者保健总裁。先灵葆雅与默克公司的合并,及160亿美元收购欧加农生物公司这两项并购业务,他都是负责人。在加入先灵葆雅之前,2000-2003,他担任普华永道的董事,及合规经营咨询部的负责人。在这之前,1998-1999,他是Coventry Health Carer的首席风险官;1995,他成为Health Care Compliance Association的合伙人。他在托马斯杰弗逊大学卫生系统开始职业生涯,担任首席合规官。除了担任博士伦董事,他还在ElectroCore LLC,the Overlook Hospital Foundation出任董事。他还是美国心脏协会纽约分会的前主席。他还是联邦储备银行纽约州北部地区咨询委员会,美国药物研究和制造商协会,和商业协会的成员。他担任着匹兹堡大学理事会成员。他获得了匹兹堡大学的学士学位,天普大学商学院工商管理硕士学位,天普大学法学院法学博士学位。
Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business.
C. David Nicholson

C. David Nicholson,2015年3月以来,他是研发总监。他于2014年8月加入公司,担任高级副总裁,负责全球品牌研发。此前,他曾担任Bayer CropScience的首席技术官兼执行副总裁,负责研发(2012年3月至2014年8月)、Merck公司的许可和知识管理副总裁(2009年至2011年12月)、Schering-Plough的高级副总裁,负责全球项目管理和药物安全(2007年至2009年)。1988年至2007年,他曾担任Organon公司的多种领导职务,在那里他最近担任执行副总裁,负责研发,也曾担任公司的执行管理委员会的成员。他持有曼彻斯特大学(University of Manchester)的学士学位,以及the University of Wales的哲学博士学位。


C. David Nicholson is Executive Vice President, Global Operations of Allergan plc. Prior to his current appointment, Mr. Swanton served as Senior Vice President Global Operations of Allergan. He joined the Company then Watson in March 2012 as Vice President, Global Supply Chain. He has extensive leadership experience in global pharmaceutical operations and managing significant business transformations. Prior to joining Allergan, Mr. Swanton held various roles at Abbott Laboratories in finance, supply chain, project management and manufacturing operations in both local and global capacities. Mr. Swanton is a Fellow of the Chartered Association of Certified Accountants, UK.
C. David Nicholson,2015年3月以来,他是研发总监。他于2014年8月加入公司,担任高级副总裁,负责全球品牌研发。此前,他曾担任Bayer CropScience的首席技术官兼执行副总裁,负责研发(2012年3月至2014年8月)、Merck公司的许可和知识管理副总裁(2009年至2011年12月)、Schering-Plough的高级副总裁,负责全球项目管理和药物安全(2007年至2009年)。1988年至2007年,他曾担任Organon公司的多种领导职务,在那里他最近担任执行副总裁,负责研发,也曾担任公司的执行管理委员会的成员。他持有曼彻斯特大学(University of Manchester)的学士学位,以及the University of Wales的哲学博士学位。
C. David Nicholson is Executive Vice President, Global Operations of Allergan plc. Prior to his current appointment, Mr. Swanton served as Senior Vice President Global Operations of Allergan. He joined the Company then Watson in March 2012 as Vice President, Global Supply Chain. He has extensive leadership experience in global pharmaceutical operations and managing significant business transformations. Prior to joining Allergan, Mr. Swanton held various roles at Abbott Laboratories in finance, supply chain, project management and manufacturing operations in both local and global capacities. Mr. Swanton is a Fellow of the Chartered Association of Certified Accountants, UK.
James C. D'Arecca

James C. D'Arecca自2013年8月起担任此职位。在加入Allergan之前,他在Bausch + Lomb担任过类似的职位。 在加入Bausch + Lomb之前,D'Arecca先生曾在Merck&Co。和先灵葆雅工作。 他还在普华永道会计师事务所担任了13年的注册会计师。 D'Arecca先生获得了哥伦比亚大学的MBA学位和他的学士学位。 在罗格斯大学会计学。


James C. D'Arecca was appointed Chief Accounting Officer - Global, on August 7 2013. Prior to joining Actavis, Mr. D'Arecca held a similar position at Bausch & Lomb. Prior to joining Bausch & Lomb, Mr. D'Arecca worked for Merck & Co., Inc. where he was Executive Director and Business Development Controller responsible for being the primary liaison between the Controller's organization and the business development and corporate licensing functions. Prior to joining Merck, Mr. D'Arecca was Executive Director and Assistant Controller at Schering-Plough. Mr. D'Arecca also spent 13 years with PricewaterhouseCoopers as a Certified Public Accountant. Mr. D'Arecca received his MBA from Columbia University and his BS in Accounting from Rutgers University.
James C. D'Arecca自2013年8月起担任此职位。在加入Allergan之前,他在Bausch + Lomb担任过类似的职位。 在加入Bausch + Lomb之前,D'Arecca先生曾在Merck&Co。和先灵葆雅工作。 他还在普华永道会计师事务所担任了13年的注册会计师。 D'Arecca先生获得了哥伦比亚大学的MBA学位和他的学士学位。 在罗格斯大学会计学。
James C. D'Arecca was appointed Chief Accounting Officer - Global, on August 7 2013. Prior to joining Actavis, Mr. D'Arecca held a similar position at Bausch & Lomb. Prior to joining Bausch & Lomb, Mr. D'Arecca worked for Merck & Co., Inc. where he was Executive Director and Business Development Controller responsible for being the primary liaison between the Controller's organization and the business development and corporate licensing functions. Prior to joining Merck, Mr. D'Arecca was Executive Director and Assistant Controller at Schering-Plough. Mr. D'Arecca also spent 13 years with PricewaterhouseCoopers as a Certified Public Accountant. Mr. D'Arecca received his MBA from Columbia University and his BS in Accounting from Rutgers University.
William Meury

William Meury,他曾一直担任我们的执行副总裁,负责商业、北美品牌(2014年7月以来)。他此前曾担任Forest Laboratories公司的执行副总裁,负责销售和营销。他于1993年加入Forest公司,担任市场营销、新产品、新业务开发和销售职务。最近,他担任高级副总裁,负责全球商业和美国销售。他负责监督几个部门的活动,包括产品管理、市场研究、商业评估,以及Forest公司的全球营销和商业化早期集团。任职Forest公司期间,他曾领导10个产品的发布。加入Forest公司之前,他曾在Reznick Fedder & Silverman公司从事公共会计,也曾在MCI Communications公司从事财务报告。他持有the University of Maryland的经济学学士学位。


William Meury is the Chief Commercial Officer of Allergan and has served in this role since May 2016 having previously served as President, Branded Pharma from March 2015 and Executive Vice President, Commercial, North American Brands from July 2014. Mr. Meury served as Executive Vice President, Sales and Marketing at Forest prior to its acquisition by Allergan then known as Actavis. He joined Forest in 1993 and held multiple roles of increasing responsibility in Marketing, New Products, Business Development, and Sales. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. He received a B.S. in Economics from the University of Maryland. Mr. Meury serves on the Board of Directors of several organizations, including The Jed Foundation, International Council of Ophthalmology Foundation, and The Allergan Foundation.
William Meury,他曾一直担任我们的执行副总裁,负责商业、北美品牌(2014年7月以来)。他此前曾担任Forest Laboratories公司的执行副总裁,负责销售和营销。他于1993年加入Forest公司,担任市场营销、新产品、新业务开发和销售职务。最近,他担任高级副总裁,负责全球商业和美国销售。他负责监督几个部门的活动,包括产品管理、市场研究、商业评估,以及Forest公司的全球营销和商业化早期集团。任职Forest公司期间,他曾领导10个产品的发布。加入Forest公司之前,他曾在Reznick Fedder & Silverman公司从事公共会计,也曾在MCI Communications公司从事财务报告。他持有the University of Maryland的经济学学士学位。
William Meury is the Chief Commercial Officer of Allergan and has served in this role since May 2016 having previously served as President, Branded Pharma from March 2015 and Executive Vice President, Commercial, North American Brands from July 2014. Mr. Meury served as Executive Vice President, Sales and Marketing at Forest prior to its acquisition by Allergan then known as Actavis. He joined Forest in 1993 and held multiple roles of increasing responsibility in Marketing, New Products, Business Development, and Sales. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. He received a B.S. in Economics from the University of Maryland. Mr. Meury serves on the Board of Directors of several organizations, including The Jed Foundation, International Council of Ophthalmology Foundation, and The Allergan Foundation.
A. Robert D. Bailey

A. Robert D. Bailey自2014年7月起担任我们的执行副总裁,首席法务官和公司秘书。2013年11月至2014年6月,他曾担任Forest的高级副总裁,首席法务官,总法律顾问和秘书。 在此之前,他于1994年开始担任Bausch + Lomb的各种职务,包括2007年至2013年担任法律,政策和通讯的执行副总裁。 在加入Bausch + Lomb之前,Bailey先生是Nixon Peabody(前Nixon Hargrave Devans&Doyle)的律师。 Bailey先生从University of Minnesota获得博士学位和 来自明尼苏达州诺斯菲尔德的 St. Olaf College的学士学位。


A. Robert D. Bailey is the Chief Legal Officer and Corporate Secretary of Allergan, and has served in this role since July 2014 having served as Senior Vice President, Chief Legal Officer, General Counsel and Corporate Secretary of Forest prior to its acquisition by Allergan, from November 2013 to June 2014. Prior to that, Mr. Bailey served as Executive Vice President, Law, Policy and Communications at Bausch + Lomb from 2007 to 2013. Before joining Bausch + Lomb in 1994 he was an attorney at Nixon Peabody formerly Nixon, Hargrave, Devans & Doyle. Mr. Bailey received his J.D. from the University of Minnesota and his B.A. from St. Olaf College in Northfield, MN.
A. Robert D. Bailey自2014年7月起担任我们的执行副总裁,首席法务官和公司秘书。2013年11月至2014年6月,他曾担任Forest的高级副总裁,首席法务官,总法律顾问和秘书。 在此之前,他于1994年开始担任Bausch + Lomb的各种职务,包括2007年至2013年担任法律,政策和通讯的执行副总裁。 在加入Bausch + Lomb之前,Bailey先生是Nixon Peabody(前Nixon Hargrave Devans&Doyle)的律师。 Bailey先生从University of Minnesota获得博士学位和 来自明尼苏达州诺斯菲尔德的 St. Olaf College的学士学位。
A. Robert D. Bailey is the Chief Legal Officer and Corporate Secretary of Allergan, and has served in this role since July 2014 having served as Senior Vice President, Chief Legal Officer, General Counsel and Corporate Secretary of Forest prior to its acquisition by Allergan, from November 2013 to June 2014. Prior to that, Mr. Bailey served as Executive Vice President, Law, Policy and Communications at Bausch + Lomb from 2007 to 2013. Before joining Bausch + Lomb in 1994 he was an attorney at Nixon Peabody formerly Nixon, Hargrave, Devans & Doyle. Mr. Bailey received his J.D. from the University of Minnesota and his B.A. from St. Olaf College in Northfield, MN.
Matthew M. Walsh

Matthew M. Walsh于2015年8月成为Multi-Color董事。他是Catalent, Inc.(制药和生物终端市场先进的交付技术和开发解决方案供应商)首席财务官。2008年4月加入Catalent之前,Walsh曾担任Escala Group首席财务官、总裁和代理首席执行官。


Matthew M. Walsh has served in this role since February 2018. Prior to joining Allergan, Mr. Walsh served as EVP, CFO at Catalent for 10 years. Before Catalent, Mr. Walsh was President, CFO and Acting CEO at Escala Group, Inc. He previously held a variety of finance leadership roles at GenTek, Inc., including Vice President-Finance & Chief Financial Officer, Vice President & Treasurer and Group Controller. Mr. Walsh is a CFA® charterholder. He received an MBA from Cornell University, SC Johnson School of Management and a Bachelor of Science in Chemical Engineering from Cornell University, College of Engineering.
Matthew M. Walsh于2015年8月成为Multi-Color董事。他是Catalent, Inc.(制药和生物终端市场先进的交付技术和开发解决方案供应商)首席财务官。2008年4月加入Catalent之前,Walsh曾担任Escala Group首席财务官、总裁和代理首席执行官。
Matthew M. Walsh has served in this role since February 2018. Prior to joining Allergan, Mr. Walsh served as EVP, CFO at Catalent for 10 years. Before Catalent, Mr. Walsh was President, CFO and Acting CEO at Escala Group, Inc. He previously held a variety of finance leadership roles at GenTek, Inc., including Vice President-Finance & Chief Financial Officer, Vice President & Treasurer and Group Controller. Mr. Walsh is a CFA® charterholder. He received an MBA from Cornell University, SC Johnson School of Management and a Bachelor of Science in Chemical Engineering from Cornell University, College of Engineering.
Karen L. Ling

Karen L. Ling自2020年4月起担任本公司董事。Ling女士自2019年7月起担任美国国际集团(American International Group,Inc。)执行副总裁兼首席人力资源官。从2015年3月到2019年7月,她在全球制药公司Allergan plc【NYSE:AGN】担任执行副总裁兼首席人力资源官。2014年7月至2015年3月,Ling女士担任全球制药公司Actavis plc的高级副总裁、人力资源和首席人力资源官。2014年1月至2014年7月,Ling女士在Forest Laboratories担任高级副总裁兼首席人力资源官,该公司在被Actavis收购之前,专注于为欧洲药品在美国的销售发放许可证。在此之前,从2011年到2014年1月,Ling女士担任默克公司(Merck&Co.,Inc。)全球人类健康和消费者护理业务全球人力资源高级副总裁。2009年11月至2011年,她还担任Merck & Co。全球薪酬和福利副总裁。2008年5月至2009年11月,在默克收购先灵葆雅之前,她担任Schering-Plough全球薪酬福利副总裁。在加入先灵葆雅之前,Ling女士曾在Wyeth, LLC担任多个职位。Ling女士是杰德基金会和扩展学校的董事会成员,这两个组织都是非盈利组织。


Karen L. Ling has served as a director of our company since April 2020. Ms. Ling has served as Executive Vice President and Chief Human Resources Officer at American International Group, Inc. [NYSE: AIG] since July 2019. From March 2015 until July 2019 she served as Executive Vice President and Chief Human Resources Officer at Allergan plc [NYSE: AGN], a global pharmaceutical company. From July 2014 until March 2015 Ms. Ling served as Senior Vice President, Human Resources and Chief Human Resources Officer at Actavis plc, a global pharmaceutical company, prior to its acquisition of Allergan and name change to Allergan. From January 2014 until July 2014 Ms. Ling was Senior Vice President and Chief Human Resources Officer at Forest Laboratories, a company which was focused on licensing European pharmaceuticals for sale in the United States, prior to its acquisition by Actavis. Prior to this, from 2011 until January 2014 Ms. Ling was Senior Vice President, Human Resources of the Global Human Health and Consumer Care businesses worldwide for Merck & Co., Inc. [NYSE: MRK]. She also served as Vice President, Global Compensation and Benefits, at Merck from November 2009 until 2011. From May 2008 until November 2009 she served as Group Vice President, Global Compensation & Benefits at Schering-Plough prior to its acquisition by Merck. Prior to joining Schering-Plough, Ms. Ling held various positions at Wyeth, LLC. Ms. Ling is a member of the board of directors of the JED Foundation and ExpandED Schools, both of which are non-profit organizations.
Karen L. Ling自2020年4月起担任本公司董事。Ling女士自2019年7月起担任美国国际集团(American International Group,Inc。)执行副总裁兼首席人力资源官。从2015年3月到2019年7月,她在全球制药公司Allergan plc【NYSE:AGN】担任执行副总裁兼首席人力资源官。2014年7月至2015年3月,Ling女士担任全球制药公司Actavis plc的高级副总裁、人力资源和首席人力资源官。2014年1月至2014年7月,Ling女士在Forest Laboratories担任高级副总裁兼首席人力资源官,该公司在被Actavis收购之前,专注于为欧洲药品在美国的销售发放许可证。在此之前,从2011年到2014年1月,Ling女士担任默克公司(Merck&Co.,Inc。)全球人类健康和消费者护理业务全球人力资源高级副总裁。2009年11月至2011年,她还担任Merck & Co。全球薪酬和福利副总裁。2008年5月至2009年11月,在默克收购先灵葆雅之前,她担任Schering-Plough全球薪酬福利副总裁。在加入先灵葆雅之前,Ling女士曾在Wyeth, LLC担任多个职位。Ling女士是杰德基金会和扩展学校的董事会成员,这两个组织都是非盈利组织。
Karen L. Ling has served as a director of our company since April 2020. Ms. Ling has served as Executive Vice President and Chief Human Resources Officer at American International Group, Inc. [NYSE: AIG] since July 2019. From March 2015 until July 2019 she served as Executive Vice President and Chief Human Resources Officer at Allergan plc [NYSE: AGN], a global pharmaceutical company. From July 2014 until March 2015 Ms. Ling served as Senior Vice President, Human Resources and Chief Human Resources Officer at Actavis plc, a global pharmaceutical company, prior to its acquisition of Allergan and name change to Allergan. From January 2014 until July 2014 Ms. Ling was Senior Vice President and Chief Human Resources Officer at Forest Laboratories, a company which was focused on licensing European pharmaceuticals for sale in the United States, prior to its acquisition by Actavis. Prior to this, from 2011 until January 2014 Ms. Ling was Senior Vice President, Human Resources of the Global Human Health and Consumer Care businesses worldwide for Merck & Co., Inc. [NYSE: MRK]. She also served as Vice President, Global Compensation and Benefits, at Merck from November 2009 until 2011. From May 2008 until November 2009 she served as Group Vice President, Global Compensation & Benefits at Schering-Plough prior to its acquisition by Merck. Prior to joining Schering-Plough, Ms. Ling held various positions at Wyeth, LLC. Ms. Ling is a member of the board of directors of the JED Foundation and ExpandED Schools, both of which are non-profit organizations.
Wayne R. Swanton

Wayne R. Swanton在Abbott Laboratories担任过各种角色,负责本地和全球的财务,供应链,项目管理和制造业务。 Swanton先生是英国特许公认会计师协会会员。


Wayne R. Swanton is Executive Vice President, Global Operations of Allergan plc. Prior to his current appointment, Mr. Swanton served as Senior Vice President Global Operations of Allergan. He joined the Company then Watson in March 2012 as Vice President, Global Supply Chain. He has extensive leadership experience in global pharmaceutical operations and managing significant business transformations. Prior to joining Allergan, Mr. Swanton held various roles at Abbott Laboratories in finance, supply chain, project management and manufacturing operations in both local and global capacities. Mr. Swanton is a Fellow of the Chartered Association of Certified Accountants, UK.
Wayne R. Swanton在Abbott Laboratories担任过各种角色,负责本地和全球的财务,供应链,项目管理和制造业务。 Swanton先生是英国特许公认会计师协会会员。
Wayne R. Swanton is Executive Vice President, Global Operations of Allergan plc. Prior to his current appointment, Mr. Swanton served as Senior Vice President Global Operations of Allergan. He joined the Company then Watson in March 2012 as Vice President, Global Supply Chain. He has extensive leadership experience in global pharmaceutical operations and managing significant business transformations. Prior to joining Allergan, Mr. Swanton held various roles at Abbott Laboratories in finance, supply chain, project management and manufacturing operations in both local and global capacities. Mr. Swanton is a Fellow of the Chartered Association of Certified Accountants, UK.
James C. D'Arecca

James C. D'Arecca自2013年8月起担任此职位。在加入Allergan之前,他在Bausch + Lomb担任过类似的职位。 在加入Bausch + Lomb之前,D'Arecca先生曾在Merck&Co。和先灵葆雅工作。 他还在普华永道会计师事务所担任了13年的注册会计师。 D'Arecca先生获得了哥伦比亚大学的MBA学位和他的学士学位。 在罗格斯大学会计学。


James C. D'Arecca has served in this role since August 2013. Prior to joining Allergan, he held a similar position at Bausch + Lomb. Prior to joining Bausch + Lomb, Mr. D'Arecca worked for Merck & Co. and Schering-Plough. He also spent 13 years with PricewaterhouseCoopers as a Certified Public Accountant. Mr. D'Arecca received his MBA from Columbia University and his B.S. in Accounting from Rutgers University.
James C. D'Arecca自2013年8月起担任此职位。在加入Allergan之前,他在Bausch + Lomb担任过类似的职位。 在加入Bausch + Lomb之前,D'Arecca先生曾在Merck&Co。和先灵葆雅工作。 他还在普华永道会计师事务所担任了13年的注册会计师。 D'Arecca先生获得了哥伦比亚大学的MBA学位和他的学士学位。 在罗格斯大学会计学。
James C. D'Arecca has served in this role since August 2013. Prior to joining Allergan, he held a similar position at Bausch + Lomb. Prior to joining Bausch + Lomb, Mr. D'Arecca worked for Merck & Co. and Schering-Plough. He also spent 13 years with PricewaterhouseCoopers as a Certified Public Accountant. Mr. D'Arecca received his MBA from Columbia University and his B.S. in Accounting from Rutgers University.
Karen Ling

Karen Ling,最近从美国国际集团(AIG)执行副总裁兼首席人力资源官的职位上退休,她自2019年7月以来一直担任该职位。在此职位上,她负责人力资本管理的各个方面,包括人才获取、培训、发展、薪酬和福利、多样性和包容性。从2014年7月到加入AIG,她曾担任Allergan plc的执行副总裁兼首席人力资源官。这是一家制药公司。在此职位上,她在转型期间制定并监督全球人力资源战略,包括成功启动新的全公司人力资源和文化计划。此前,她曾担任Merck & Co., Inc.全球人类健康和消费者护理业务的人力资源高级副总裁。在加入默克公司之前,她曾担任先灵葆雅全球薪酬与福利集团副总裁。Ling女士还在Wyeth工作了14年,担任各种职位,负责业务部门的人力资源战略开发,并在Wyeth的劳动和就业部门工作。Ling女士拥有波士顿大学法学院的法学博士学位和耶鲁大学的经济学学士学位。


Karen Ling,recently retired from her role as Executive Vice President and Chief Human Resources Officer for American International Group, Inc. ("AIG"), a position she had held since July 2019. In this role, Ms. Ling oversaw all aspects of human capital management, including talent acquisition, training, development, compensation and benefits, and diversity and inclusion. From July 2014 until joining AIG, Ms. Ling served as Executive Vice President and Chief Human Resources Officer at Allergan plc., a pharmaceutical company. In this capacity, Ms. Ling developed and oversaw a global HR strategy during a period of transition that included successfully launching new company-wide HR resources and cultural initiatives. Previously Ms. Ling was Senior Vice President, Human Resources for Merck & Co., Inc.'s Global Human Health and Consumer Care businesses worldwide. Prior to Merck, she was Group Vice President, Global Compensation & Benefits at Schering-Plough. Ms. Ling also spent 14 years at Wyeth in various positions of increasing responsibility developing HR strategies for business units and working in Wyeth's Labor & Employment Department. Ms. Ling holds a JD from Boston University School of Law and a B.A. in Economics from Yale University.
Karen Ling,最近从美国国际集团(AIG)执行副总裁兼首席人力资源官的职位上退休,她自2019年7月以来一直担任该职位。在此职位上,她负责人力资本管理的各个方面,包括人才获取、培训、发展、薪酬和福利、多样性和包容性。从2014年7月到加入AIG,她曾担任Allergan plc的执行副总裁兼首席人力资源官。这是一家制药公司。在此职位上,她在转型期间制定并监督全球人力资源战略,包括成功启动新的全公司人力资源和文化计划。此前,她曾担任Merck & Co., Inc.全球人类健康和消费者护理业务的人力资源高级副总裁。在加入默克公司之前,她曾担任先灵葆雅全球薪酬与福利集团副总裁。Ling女士还在Wyeth工作了14年,担任各种职位,负责业务部门的人力资源战略开发,并在Wyeth的劳动和就业部门工作。Ling女士拥有波士顿大学法学院的法学博士学位和耶鲁大学的经济学学士学位。
Karen Ling,recently retired from her role as Executive Vice President and Chief Human Resources Officer for American International Group, Inc. ("AIG"), a position she had held since July 2019. In this role, Ms. Ling oversaw all aspects of human capital management, including talent acquisition, training, development, compensation and benefits, and diversity and inclusion. From July 2014 until joining AIG, Ms. Ling served as Executive Vice President and Chief Human Resources Officer at Allergan plc., a pharmaceutical company. In this capacity, Ms. Ling developed and oversaw a global HR strategy during a period of transition that included successfully launching new company-wide HR resources and cultural initiatives. Previously Ms. Ling was Senior Vice President, Human Resources for Merck & Co., Inc.'s Global Human Health and Consumer Care businesses worldwide. Prior to Merck, she was Group Vice President, Global Compensation & Benefits at Schering-Plough. Ms. Ling also spent 14 years at Wyeth in various positions of increasing responsibility developing HR strategies for business units and working in Wyeth's Labor & Employment Department. Ms. Ling holds a JD from Boston University School of Law and a B.A. in Economics from Yale University.